



Abilify® Maintena®
(aripiprazole extended-release injection)
Effective May 1, 2018

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Abilify Maintena is a second-generation atypical antipsychotic indicated for treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

Coverage Guidelines

Approval of Abilify Maintena will be granted if the member meets all following criteria and documentation has been submitted:

1. The member is at least 18 years of age **AND**
2. The member has had a documented ineffective response, side effect, allergy or contraindication to a trial of Aristada® (aripiprazole lauroxil)

Continuation of Therapy

Reauthorization requires documentation by prescriber that indicates stability and adherence.

Limitations

Approvals will be granted for up to 1 year

Review History

05/01/18 – Implemented MassHealth PDS

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.